close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

(OP:RLFTY)

3.810 -0.040 (-1.04%)
Streaming Delayed Price Updated: 9:36 AM EDT, Oct 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 771
Open 3.810
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 3.850
Today's Range 3.810 - 3.810
52wk Range 2.345 - 7.710
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Relief Therapeutics Publishes 2025 Half-Year Report
Via ACCESS Newswire
Relief Therapeutics Advances Publication of 2025 Half-Year Report
Via ACCESS Newswire

Performance

YTD
-22.2%
-22.2%
1 Month
-9.9%
-9.9%
3 Month
+5.5%
+5.5%
6 Month
+17.2%
+17.2%
1 Year
-47.1%
-47.1%

More News

Read More
Relief Therapeutics Announces Proposed Business Combination with NeuroX, Successor to MindMaze
Via ACCESS Newswire
Relief Therapeutics Receives FDA Response to QIDP Request for RLF-TD011
Via ACCESS Newswire
Relief Therapeutics Announces Final Readout of PKU GOLIKE Clinical Trial
Via ACCESSWIRE
Relief Therapeutics Announces Filing of Form 15F to Terminate SEC Reporting Obligations
Via ACCESSWIRE
Relief Therapeutics Reports Half-Year 2024 Financial Results and Provides Corporate Update
Via ACCESSWIRE
Relief Therapeutics Announces Results of Annual General Meeting
Via ACCESS Newswire
Relief Therapeutics Receives FDA Rare Pediatric Disease Designation for RLF-TD011
Via ACCESS Newswire
Relief Therapeutics Publishes 2025 Annual General Meeting Agenda
Via ACCESS Newswire
Relief Therapeutics Reports 2024 Financial Results and Provides Corporate Update
Via ACCESS Newswire
Relief Therapeutics Secures up to $11 Million from Royalty Sales
Via ACCESSWIRE
Relief Therapeutics Announces Conclusion of Merger Discussions with Renexxion
Via ACCESS Newswire
Relief Therapeutics Announces European Patent Office Decision to Grant Patent for RLF-TD011
Via ACCESS Newswire
Relief Therapeutics Completes Strategic Transition with Sale of GOLIKE Rights ex-US
Via ACCESS Newswire
Relief Therapeutics Provides Update on Potential Transaction with Renexxion
Via ACCESSWIRE
Relief Therapeutics Announces Positive Final Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa
Via ACCESSWIRE
Relief Therapeutics Signs Non-Binding Letter of Intent with Renexxion for Reverse Merger
Via ACCESSWIRE
Relief Therapeutics Announces Publication of Plain Language Summary on PKU GOLIKE
Via ACCESSWIRE
Relief Therapeutics Reports New Study Results for RLF-OD032 and Files Provisional Patents
Via ACCESSWIRE
Relief Therapeutics Receives Notice of Allowance for European Patent Covering RLF-TD011 for Epidermolysis Bullosa Wound Treatment
Via ACCESSWIRE
Relief Therapeutics Announces Promising Preliminary Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa
Via ACCESSWIRE
Relief Therapeutics Reports Positive Results from RLF-OD032 Proof-of-Concept Clinical Study for Phenylketonuria
Via ACCESSWIRE
Relief Therapeutics Completes Clinical Phase in RLF-OD032 Proof-of-Concept Study; Topline Results Expected in October 2024
Via ACCESSWIRE
Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024
Via ACCESSWIRE

Frequently Asked Questions

Is RLFTY publicly traded?
Yes, RLFTY is publicly traded.
What exchange does RLFTY trade on?
RLFTY trades on the OTC Traded
What is the ticker symbol for RLFTY?
The ticker symbol for RLFTY is RLFTY on the OTC Traded
What is the current price of RLFTY?
The current price of RLFTY is 3.810
When was RLFTY last traded?
The last trade of RLFTY was at 10/24/25 09:36 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today